Viola Alesi
Thomas Jefferson University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Viola Alesi.
European Journal of Human Genetics | 2010
Laura Bernardini; Viola Alesi; Sara Loddo; Antonio Novelli; Irene Bottillo; Agatino Battaglia; Maria Cristina Digilio; Giuseppe Zampino; Adam Ertel; Paolo Fortina; Saul Surrey; Bruno Dallapiccola
We used Affymetrix 6.0 GeneChip SNP arrays to characterize copy number variations (CNVs) in a cohort of 70 patients previously characterized on lower-density oligonucleotide arrays affected by idiopathic mental retardation and dysmorphic features. The SNP array platform includes ∼900 000 SNP probes and 900 000 non-SNP oligonucleotide probes at an average distance of 0.7 Kb, which facilitates coverage of the whole genome, including coding and noncoding regions. The high density of probes is critical for detecting small CNVs, but it can lead to data interpretation problems. To reduce the number of false positives, parameters were set to consider only imbalances >75 Kb encompassing at least 80 probe sets. The higher resolution of the SNP array platform confirmed the increased ability to detect small CNVs, although more than 80% of these CNVs overlapped to copy number ‘neutral’ polymorphism regions and 4.4% of them did not contain known genes. In our cohort of 70 patients, of the 51 previously evaluated as ‘normal’ on the Agilent 44K array, the SNP array platform disclosed six additional CNV changes, including three in three patients, which may be pathogenic. This suggests that about 6% of individuals classified as ‘normal’ using the lower-density oligonucleotide array could be found to be affected by a genomic disorder when evaluated with the higher-density microarray platforms.
American Journal of Medical Genetics Part A | 2014
Eric Londin; Jeffrey Adijanto; Nancy J. Philp; Antonio Novelli; Emilia Vitale; Chiara Perria; Gigliola Serra; Viola Alesi; Saul Surrey; Paolo Fortina
X‐linked intellectual disability is the most common form of cognitive disability in males. Syndromic intellectual disability encompasses cognitive deficits with other medical and behavioral manifestations. Recently, a large family with a novel form of syndromic X‐linked intellectual disability was characterized. Eight of 24 members of the family are male and had cognitive dysfunction, short stature, aphasia, skeletal abnormalities, and minor anomalies. To identify the causative gene(s), we performed exome sequencing in three affected boys, both parents, and an unaffected sister. We identified a haplotype consisting of eight variants located in cis within the linkage region that segregated with affected members in the family. Of these variants, two were novel. The first was at the splice‐donor site of intron 7 (c.974+1G>T) in the cullin‐RING ubiquitin ligase (E3) gene, CUL4B. This variant is predicted to result in failure to splice and remove intron 7 from the primary transcript. The second variant mapped to the 3′‐UTR region of the KAISO gene (c.1127T>G). Sanger sequencing validated the variants in these relatives as well as in three affected males and five carriers. The KAISO gene variant was predicted to create a binding site for the microRNAs miR‐4999 and miR‐4774; however, luciferase expression assays failed to validate increased targeting of these miRNAs to the variant 3′‐UTR. This SNP may affect 3′‐UTR structure leading to decreased mRNA stability. Our results suggest that the intellectual disability phenotype in this family is caused by aberrant splicing and removal of intron 7 from CUL4B gene primary transcript.
Gene | 2012
Viola Alesi; Marta Bertoli; Giuseppe Barrano; Barbara Torres; Silvia Pusceddu; Myriam Pastorino; Chiara Perria; Anna Maria Nardone; Antonio Novelli; Gigliola Serra
About 10% of causative mutations for mental retardation in male patients involve X chromosome (X-linked mental retardation, XLMR). We describe a case of a 3-year-old boy presenting with developmental delay, autistic features and growth and speech delay. Array-CGH analysis detected a microduplication on the X chromosome (Xp11.2p11.3), spanning 335.4 kb and including 3 known genes (ZNF81, ZNF182 and SPACA5). Genome-wide association studies show that approximately 30% of mutations causing XLMR are located in Xp11.2p11.3, where few pathogenic genes have been identified to date (such as ZNF41, PQB1 and ZNF81). ZNF81 codifies a zinc finger protein and mutations (non-sense mutations, deletions and structural rearrangements) involving this gene have already been described in association with mental retardation. Larger duplications in the same region have also been observed in association with mental retardation, and, in one case, the over-expression of ZNF81 has also been verified by mRNA quantification. No duplications of the single gene have been identified. To our knowledge, the microduplication found in our patient is the smallest ever described in Xp11.2p11.3. This suggests that the over-expression of ZNF81 could have pathological effects.
American Journal of Medical Genetics Part A | 2011
Viola Alesi; Giuseppe Barrano; Sara Morara; Daria Darelli; Katia Petrilli; Anna Capalbo; Mario Pacella; Cristina Haass; Maurizio Finocchi; Antonio Novelli; Marta Bertoli
Interstitial deletion of the short arm of chromosome 4, excluding cytoband p16, has been described as a distinct phenotype from the Wolf–Hirschhorn syndrome, characterized by a deletion encompassing cytoband p16. We report on the case of a 14‐month‐old boy with an apparently isolated craniosynostosis and harboring a de novo microdeletion in band 4p15. The imbalance, about 4 Mb in size is, to date, the smallest deletion ever described in this region, encompassing 12 genes. A comparison with other previously described cases of 4p15 deletion is made, and the possible roles of some genes involved in the deletion are discussed.
Journal of Genetic Syndromes & Gene Therapy | 2016
Viola Alesi; Laura Bernardini; Didier Goidin; Michela Canestrelli; Maria Lisa Dentici; Giuseppe Barrano; Maria Grazia Giuffrida; Anna Maria Nardone; Diana Postorivo; Luigi Laino; Rita Genesio; Bruno Dallapiccola; Antonio Novelli
Over last decade chromosome microarray analysis has become a routine test, but its use as first tier in prenatal diagnosis still raises disputes specially when applied to low risk pregnancies. In order to limit the identification of incidental findings (IF) and variants of unknown significance (VOUS) we designed EasyChip, a low-resolution oligonucleotide array CGH platform with a functional resolution of 3 Mb in genomic backbone, 300 Kb in sub-telomeric regions, and 150 Kb in 43 regions associated with syndromic disorders, selected considering morbidity, penetrance, and etiological mechanisms. After an “in silico” evaluation, which showed that Easychip would not uncover most of VOUS (24% vs 3%) and any IF, we have validated EasyChip on 169 patients samples, 57 retrospective samples with known imbalances and 112 prospective samples as part of the prenatal diagnosis process. All the known rearrangements were detected and 7 further pathogenic imbalances were detected on the still undiagnosed cohort. To evaluate false positive/negative rate, thirty-eight out of the 112 prospective samples were also processed on an high resolution array CGH, allowing comparing the results in term of diagnostic utility and impact on detection rate. Two positive and pathogenic results were detected by both platforms. EasyChip did not detect 10 of the 11 VOUS nor 2 IF discovered by the high-resolution platform. In conjunction with karyotype, EasyChip is a useful tool in prenatal diagnosis for screening purposes on low risk pregnancies, it enables the detection of cryptic imbalanced subtelomeric rearrangements, microdeletions/duplications within 43 syndromic regions and supports standard cytogenetic analysis at whole genome level. Finally, this tool, differently from higher resolution platforms, significantly reduces the detection rate of VOUS and IF, which represent a major drawback during genetic counselling specially for low risk pregnancies, significantly reduces the time to spend on analysis and limit the need of additional confirmation.
Neurogenetics | 2018
Lorena Travaglini; Chiara Aiello; Fabrizia Stregapede; Adele D’Amico; Viola Alesi; Andrea Ciolfi; Alessandro Bruselles; Michela Catteruccia; Simone Pizzi; Ginevra Zanni; Sara Loddo; Sabina Barresi; Gessica Vasco; Marco Tartaglia; Enrico Bertini; Francesco Nicita
Hereditary spastic paraplegias (HSP) are clinical and genetic heterogeneous diseases with more than 80 disease genes identified thus far. Studies on large cohorts of HSP patients showed that, by means of current technologies, the percentage of genetically solved cases is close to 50%. Notably, the percentage of molecularly confirmed diagnoses decreases significantly in sporadic patients. To describe our diagnostic molecular genetic approach on patients with pediatric-onset pure and complex HSP, 47 subjects with HSP underwent molecular screening of 113 known and candidate disease genes by targeted capture and massively parallel sequencing. Negative cases were successively analyzed by multiplex ligation-dependent probe amplification (MLPA) analysis for the SPAST gene and high-resolution SNP array analysis for genome-wide CNV detection. Diagnosis was molecularly confirmed in 29 out of 47 (62%) patients, most of whom had clinical diagnosis of cHSP. Although SPG11 and SPG4 remain the most frequent cause of, respectively, complex and pure HSP, a large number of pathogenic variants were disclosed in POLR3A, FA2H, DDHD2, ATP2B4, ENTPD1, ERLIN2, CAPN1, ALS2, ADAR1, RNASEH2B, TUBB4A, ATL1, and KIF1A. In a subset of these disease genes, phenotypic expansion and novel genotype-phenotype correlations were recognized. Notably, SNP array analysis did not provide any significant contribution in increasing the diagnostic yield. Our findings document the high diagnostic yield of targeted sequencing for patients with pediatric-onset, complex, and pure HSP. MLPA for SPAST and SNP array should be limited to properly selected cases based on clinical suspicion.
Clinical Genetics | 2018
Emanuele Agolini; Maria Lisa Dentici; Emanuele Bellacchio; Viola Alesi; Francesca Clementina Radio; Annalaura Torella; Francesco Musacchia; Marco Tartaglia; Bruno Dallapiccola; Vincenzo Nigro; Maria Cristina Digilio; Antonio Novelli
Protein arginine methyltransferase 7 (PRMT7) is a member of a family of enzymes that catalyze the transfer of methyl groups from S‐adenosyl‐l‐methionine to nitrogen atoms on arginine residues. Arginine methylation is involved in multiple biological processes, such as signal transduction, mRNA splicing, transcriptional control, DNA repair, and protein translocation. Currently, 7 patients have been described harboring compound heterozygous or homozygous variants in the PRMT7 gene, causing a novel intellectual disability syndrome, known as SBIDDS syndrome (Short Stature, Brachydactyly, Intellectual Developmental Disability, and Seizures).
American Journal of Medical Genetics Part A | 2018
Laura Bernardini; Francesca Clementina Radio; Fabio Acquaviva; Cristina Gorgone; Diana Postorivo; Barbara Torres; Viola Alesi; Monia Magliozzi; Fortunato Lonardo; Matteo Della Monica; Anna Maria Nardone; Claudia Cesario; Teresa Mattina; Gioacchino Scarano; Bruno Dallapiccola; Maria Cristina Digilio; Antonio Novelli
Wolf–Hirschhorn syndrome is a well‐defined disorder due to 4p16.3 deletion, characterized by distinct facial features, intellectual disability, prenatal and postnatal growth retardation, and seizures. Genotype–phenotype correlations based on differently sized deletions have been attempted, and some candidate genes have been suggested. We report on clinical characteristics of three patients with pure interstitial submicroscopic 4p16.3 deletions, ranging in size from 68 to 166 kb, involving WHSCR1 and/or part of WHSCR2, and review published cases with overlapping 4p16.3 losses. The present study highlights a major role of NSD2 gene in the pathogenesis of the WHS main features and predicts that loss‐of‐function mutations affecting NSD2 gene could result in microcephaly, prenatal and postnatal growth retardation, psychomotor and language delay, and craniofacial features. Absent seizures in all subjects corroborate the suggestion that this specific feature is causally linked with at least one additional causative gene. Finally, we suggest that mir‐943 could play a role in the pathogenesis of CHD in some of these patients.
American Journal of Medical Genetics | 2018
Kate Wolfe; Andrew McQuillin; Viola Alesi; Elise Boudry Labis; Peter Cutajar; Bruno Dallapiccola; Maria Lisa Dentici; Anne Dieux-Coeslier; Benedicte Duban-Bedu; Tina Duelund Hjortshøj; Himanshu Goel; Sara Loddo; Deborah Morrogh; Anne-Laure Mosca-Boidron; Antonio Novelli; Laurence Olivier-Faivre; Jennifer Parker; Michael J. Parker; Christine Patch; Anna L Pelling; Thomas Smol; Zeynep Tümer; Olivier Vanakker; Arie van Haeringen; Clémence Vanlerberghe; Andre Strydom; David Skuse; Nick Bass
Recurrent deletions and duplications at the 2q13 locus have been associated with developmental delay (DD) and dysmorphisms. We aimed to undertake detailed clinical characterization of individuals with 2q13 copy number variations (CNVs), with a focus on behavioral and psychiatric phenotypes. Participants were recruited via the Unique chromosomal disorder support group, U.K. National Health Service Regional Genetics Centres, and the DatabasE of genomiC varIation and Phenotype in Humans using Ensembl Resources (DECIPHER) database. A review of published 2q13 patient case reports was undertaken to enable combined phenotypic analysis. We present a new case series of 2q13 CNV carriers (21 deletion, 4 duplication) and the largest ever combined analysis with data from published studies, making a total of 54 deletion and 23 duplication carriers. DD/intellectual disabilities was identified in the majority of carriers (79% deletion, 70% duplication), although in the new cases 52% had an IQ in the borderline or normal range. Despite the median age of the new cases being only 9 years, 64% had a clinical psychiatric diagnosis. Combined analysis found attention deficit hyperactivity disorder (ADHD) to be the most frequent diagnosis (48% deletion, 60% duplication), followed by autism spectrum disorders (33% deletion, 17% duplication). Aggressive (33%) and self‐injurious behaviors (33%) were also identified in the new cases. CNVs at 2q13 are typically associated with DD with mildly impaired intelligence, and a high rate of childhood psychiatric diagnoses—particularly ADHD. We have further characterized the clinical phenotype related to imbalances of the 2q13 region and identified it as a region of interest for the neurobiological investigation of ADHD.
Cytogenetic and Genome Research | 2017
Seçil Vural; Pelin Ertop; Ceren D. Durmaz; Hatice Şanlı; Aylin Okçu Heper; Nihal Kundakci; Halil Gürhan Karabulut; Hatice Ilgın Ruhi; Tiago Marafiga Degrandi; Analía Del Valle Garnero; Patricia C. M. O'Brien; Malcolm A. Ferguson-Smith; Rafael Kretschmer; Viola Alesi; Valeria Orlando; Silvia Genovese; Sara Loddo; Elisa Pisaneschi; Daniele Pompili; Cecilia Surace; Fabrizia Restaldi; Maria Cristina Digilio; Bruno Dallapiccola; Maria Lisa Dentici; Antonio Novelli; Michael Schmid; Claus Steinlein; Lisa De Lorenzi; A. Iannuzzi; Elena Rossi
Plant cytogenetics and genomics Andreas Houben Institute of Plant Genetics and Crop Plant, Research (IPK) Corrents-Str. 3 Gatersleben, D–06466 (Germany) Tel. (+1) 785 532 2364; Fax (+1) 785 532 5692 E-mail: [email protected] Tumor cell genetics and cancer cytogenetics Ad Geurts Van Kessel Department of Human Genetics University Hospital P.O. Box 9101 NL–6500 HB Nijmegen (The Netherlands) Tel. (+31) 24 361 4107; Fax (+31) 24 354 0488 E-mail: [email protected]